Skip to main content

Visqid AA Disease Interactions

There are 6 disease interactions with Visqid AA (methenamine / sodium acid phosphate).

Major

Methenamine (applies to Visqid AA) crystalluria

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction, Dehydration

The use of methenamine salts (i.e. methenamine hippurate or mandelate), but not the base, is contraindicated in patients with severe renal impairment or dehydration. Methenamine is excreted by the kidney and concentrated in the urine. In patients with low urinary output, the salts can precipitate and cause crystalluria.

References

  1. Klinge E, Mannisto P, Mantyla R, Lamminsivu U, Ottoila P (1982) "Pharmacokinetics of methenamine in healthy volunteers." J Antimicrob Chemother, 9, p. 209-16
  2. Gleckman R, Alvarez S, Joubert D, Matthews S (1979) "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm, 36, p. 1509-12
  3. Australian Drug Evaluation Committee (1972) "Adverse effects of drugs commonly used in the treatment of urinary tract infection." Med J Aust, 1, p. 435-8
  4. (2002) "Product Information. Hiprex (methenamine)." Hoechst Marion Roussel
  5. (2002) "Product Information. Mandelamine (methenamine)." Parke-Davis
  6. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
View all 6 references
Major

Methenamine (applies to Visqid AA) gout

Major Potential Hazard, Moderate plausibility.

Methenamine mandelate (salts), should be avoided in patients with gout as it may precipitate urate crystals in their urine. A similar situation may arise in patients with a predisposition to the formation of uric acid stones.

References

  1. (2002) "Product Information. Hiprex (methenamine)." Hoechst Marion Roussel
Major

Methenamine (applies to Visqid AA) liver disease

Major Potential Hazard, High plausibility.

The use of methenamine and its salts (i.e. methenamine hippurate or mandelate) is contraindicated in patients with severe hepatic impairment. Methenamine is hydrolyzed to ammonia and formaldehyde in the urine under acidic conditions. Patients with liver disease may already have elevated ammonia levels, which can cause or exacerbate hepatic encephalopathy. Methenamine hippurate has also been associated with isolated cases of transient elevations in serum transaminases. The manufacturer recommends periodic liver function tests during therapy, particularly in patients with preexisting liver dysfunction.

References

  1. Strom J, Jun H (1975) "Kinetics of hydrolysis of methenamine." Pharm Bull, 23, p. 651
  2. Gleckman R, Alvarez S, Joubert D, Matthews S (1979) "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm, 36, p. 1509-12
  3. (2002) "Product Information. Hiprex (methenamine)." Hoechst Marion Roussel
  4. (2002) "Product Information. Mandelamine (methenamine)." Parke-Davis
  5. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
View all 5 references
Major

Phosphates (applies to Visqid AA) hypocalcemia

Major Potential Hazard, High plausibility. Applicable conditions: Pancreatitis, Hyperkalemia

The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.

References

  1. (2001) "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals
  2. (2001) "Product Information. Fleet Enema (sodium acid phophate-sodium phosphate)." Fleet
Major

Phosphates (applies to Visqid AA) phosphate imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Hypoparathyroidism, Renal Dysfunction

Therapy with phosphates should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Elevated serum concentrations of phosphate and calcium can exceed the solubility level and result in calcium-phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

References

  1. (2001) "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals
  2. (2001) "Product Information. Fleet Enema (sodium acid phophate-sodium phosphate)." Fleet
Major

Sodium salts (applies to Visqid AA) sodium/water imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Hypokalemia, Fluid Retention, Hypernatremia

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

References

  1. (2001) "Product Information. Megace (megestrol)." Bristol-Myers Squibb
  2. (2001) "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company
  3. (2001) "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals

Visqid AA drug interactions

There are 62 drug interactions with Visqid AA (methenamine / sodium acid phosphate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer